These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 29903434)
1. Value of a Statistical Model Based on Four Kallikrein Markers in Blood, Commercially Available as 4Kscore, in All Reasonable Prostate Biopsy Subgroups. Vickers AJ; Vertosick EA; Sjoberg DD Eur Urol; 2018 Oct; 74(4):535-536. PubMed ID: 29903434 [No Abstract] [Full Text] [Related]
2. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548 [TBL] [Abstract][Full Text] [Related]
3. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698 [TBL] [Abstract][Full Text] [Related]
4. 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening. McDonald ML; Parsons JK Urol Clin North Am; 2016 Feb; 43(1):39-46. PubMed ID: 26614027 [TBL] [Abstract][Full Text] [Related]
5. Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort. Lonergan PE; Vertosick EA; Assel M; Sjoberg DD; Haese A; Graefen M; Boorjian SA; Klee GG; Cooperberg MR; Pettersson K; Routila E; Vickers AJ; Lilja H BJU Int; 2021 Aug; 128(2):218-224. PubMed ID: 33306251 [TBL] [Abstract][Full Text] [Related]
6. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334 [TBL] [Abstract][Full Text] [Related]
7. Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer. Punnen S; Nahar B; Soodana-Prakash N; Koru-Sengul T; Stoyanova R; Pollack A; Kava B; Gonzalgo ML; Ritch CR; Parekh DJ PLoS One; 2018; 13(8):e0201384. PubMed ID: 30092002 [TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen or human kallikrein 3? Recent developments. Diamandis EP Tumour Biol; 1998; 19(2):65-7; discussion 67-8. PubMed ID: 9486557 [No Abstract] [Full Text] [Related]
9. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. Vickers A; Vertosick EA; Sjoberg DD; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H J Urol; 2018 Jun; 199(6):1470-1474. PubMed ID: 29366640 [TBL] [Abstract][Full Text] [Related]
10. Beyond PSA: The Role of Prostate Health Index (phi). Ferro M; De Cobelli O; Lucarelli G; Porreca A; Busetto GM; Cantiello F; Damiano R; Autorino R; Musi G; Vartolomei MD; Muto M; Terracciano D Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32053990 [TBL] [Abstract][Full Text] [Related]
11. Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years. Vertosick EA; Häggström C; Sjoberg DD; Hallmans G; Johansson R; Vickers AJ; Stattin P; Lilja H J Urol; 2020 Aug; 204(2):281-288. PubMed ID: 32125228 [TBL] [Abstract][Full Text] [Related]
12. Concordance and Performance of 4Kscore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer. Wysock JS; Becher E; Persily J; Loeb S; Lepor H Urology; 2020 Jul; 141():119-124. PubMed ID: 32294481 [TBL] [Abstract][Full Text] [Related]
13. A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer. Bhattu AS; Zappala SM; Parekh DJ; Punnen S Urology; 2021 Feb; 148():53-58. PubMed ID: 33217456 [TBL] [Abstract][Full Text] [Related]
14. A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men. Punnen S; Freedland SJ; Polascik TJ; Loeb S; Risk MC; Savage S; Mathur SC; Uchio E; Dong Y; Silberstein JL J Urol; 2018 Jun; 199(6):1459-1463. PubMed ID: 29223389 [TBL] [Abstract][Full Text] [Related]
15. The Kallikrein Panel for prostate cancer screening: its economic impact. Voigt JD; Zappala SM; Vaughan ED; Wein AJ Prostate; 2014 Feb; 74(3):250-9. PubMed ID: 24166488 [TBL] [Abstract][Full Text] [Related]